Advertisement
Through the acquisition of Sirtris, GSK has significantly enhanced itsmetabolic, neurology, immunology and inflammation research efforts byestablishing a presence in the field of sirtuins, a recently discovered classof enzymes that is believed to be involved in the ageing process.
Advertisement
Sirtris will become part of GSK's Drug Discovery organization, whilecontinuing to operate from laboratories in Cambridge, Massachusetts, as anautonomous drug discovery unit. Christoph Westphal, CEO and Vice Chair ofSirtris, and the management team will continue to lead this autonomous unit.
About GSK
GSK -- one of the world's leading research-based pharmaceutical andhealthcare companies -- is committed to improving the quality of human life byenabling people to do more, feel better and live longer. For companyinformation including a copy of this announcement and details of the company'supdated product development pipeline, visit GSK at www.gsk.com.
SOURCE GlaxoSmithKline
